Amarin Corp Plcuk (AMRN) Change in Acquisitions & Divestments (2020 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Change in Acquisitions & Divestments of $42.5 million for Q1 2026, down 22.73% YoY from $55.0 million in Q1 2025, and down 9.58% sequentially from $47.0 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Change in Acquisitions & Divestments (2020 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Change in Acquisitions & Divestments across 7 years of filings, most recently posting $42.5 million for Q1 2026.
- In Q1 2026, Change in Acquisitions & Divestments fell 22.73% year-over-year to $42.5 million; the TTM figure through Mar 2026 stood at $196.8 million (down 12.84% YoY), while the FY2025 annual figure was $209.3 million, down 10.09% from the prior year.
- Change in Acquisitions & Divestments eased to $42.5 million in Q1 2026, from $47.0 million in the prior quarter.
- Over the last five years, Change in Acquisitions & Divestments for AMRN reached as high as $113.2 million in Q1 2022 and fell as low as $16.9 million in Q4 2022.
- The 5-year median for Change in Acquisitions & Divestments is $54.2 million (2022), against an average of $54.8 million.
- Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments plunged 79.42% — and 2024, when it soared 88.38%.
- A 5-year view of Change in Acquisitions & Divestments shows it stood at $16.9 million in 2022, then soared by 72.19% to $29.1 million in 2023, then jumped by 61.45% to $47.0 million in 2024, then gained by 0.0% to $47.0 million in 2025, then slipped by 9.58% to $42.5 million in 2026.
- According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $42.5 million, $47.0 million, and $57.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.50 Mn |
| Mar 31, 2026 | 42.50 Mn |
| Dec 31, 2025 | 47.00 Mn |
| Dec 31, 2025 | 47.00 Mn |
| Sep 30, 2025 | 57.00 Mn |
| Sep 30, 2025 | 57.00 Mn |
| Jun 30, 2025 | 50.30 Mn |
| Jun 30, 2025 | 50.30 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Dec 31, 2024 | 47.00 Mn |
| Dec 31, 2024 | 47.00 Mn |
| Sep 30, 2024 | 52.80 Mn |
| Sep 30, 2024 | 52.80 Mn |
| Jun 30, 2024 | 71.00 Mn |
| Jun 30, 2024 | 71.00 Mn |
| Mar 31, 2024 | 62.00 Mn |
| Mar 31, 2024 | 62.00 Mn |
| Dec 31, 2023 | 29.11 Mn |
| Dec 31, 2023 | 29.11 Mn |